| アブストラクト | PURPOSE: The optimal design for pharmacoepidemiologic drug-drug interactions (DDIs) studies is unclear. Using the association between concomitant use of sulfonylureas and warfarin and the risk of severe hypoglycemia as a case study, a DDI with little or no clinical impact, we tested whether the prevalent new-user design can be applied in the area. METHODS: Among all patients initiating sulfonylureas in the UK's Clinical Practice Research Datalink (1998-2020), we identified those adding-on warfarin while on a sulfonylurea. For each co-exposed patient, we defined a prescription-based exposure set including other sulfonylurea users not adding-on warfarin (comparators). Within each exposure set, we matched each co-exposed patient to five comparators on time-conditional propensity scores (TCPS) and followed them using an as-treated approach. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) of severe hypoglycemia associated with concomitant use of sulfonylureas and warfarin compared to use of sulfonylureas alone. Sensitivity analyses addressed the impact of different potential sources of bias. RESULTS: The study cohort included 17 890 patients co-exposed to sulfonylureas and warfarin and 88 749 matched comparators. After TCPS matching, patient characteristics were well-balanced between groups. Compared to use of sulfonylureas alone, concomitant use of sulfonylureas and warfarin was not associated with the risk of severe hypoglycemia (HR, 1.04; 95% CI, 0.92-1.17). Sensitivity analyses were consistent with the primary analysis (HRs ranging from 1.01 to 1.15, all not statistically significant). CONCLUSIONS: Our study suggests that the prevalent new-user design could be used for the assessment of clinical effects of DDIs. |
|---|
| ジャーナル名 | Pharmacoepidemiology and drug safety |
|---|
| 投稿日 | 2024/10/8 |
|---|
| 投稿者 | Wang, Wanqi; Cui, Ying; Yu, Oriana Hoi Yun; Suissa, Samy; Douros, Antonios |
|---|
| 組織名 | Department of Epidemiology, Biostatistics and Occupational Health, McGill;University, Montreal, Quebec, Canada.;Centre for Clinical Epidemiology, Lady Davis Institute, Montreal, Quebec, Canada.;Division of Endocrinology and Metabolism, Jewish General Hospital/McGill;Department of Medicine, McGill University, Montreal, Quebec, Canada.;Institute of Clinical Pharmacology and Toxicology, Charite - Universitatsmedizin;Berlin, Berlin, Germany. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39375929/ |
|---|
